# Relative Bioavailability Study of HU6

> **NCT06486558** · PHASE1 · COMPLETED · sponsor: **Rivus Pharmaceuticals, Inc.** · enrollment: 43 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** HU6 450 mg Tablet
- **DRUG:** HU6 150 mg Capsules x 3 (Total dose = 450 mg)

## Key facts

- **NCT ID:** NCT06486558
- **Lead sponsor:** Rivus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-24
- **Primary completion:** 2024-11-15
- **Final completion:** 2024-12-15
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2025-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06486558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06486558, "Relative Bioavailability Study of HU6". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06486558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*